Proarrhythmic effects offlecainide acetate have been reported during exercise, but the mechanism for the arrhythmogenic interaction between flecainide and exercise is unknown. We hypothesized that the sinus tachycardia of exercise may enhance flecainide-induced conduction slowing by increasing use-dependent sodium channel blockade, thereby facilitating the occurrence of ventricular reentry. To evaluate the modulation of flecainide's effects by exercise, we studied 19 patients who were receiving therapeutic doses of flecainide for the treatment of cardiac arrhythmias. Sixteen patients underwent treadmill exercise testing by a modified Bruce protocol.
Proarrhythmic effects offlecainide acetate have been reported during exercise, but the mechanism for the arrhythmogenic interaction between flecainide and exercise is unknown. We hypothesized that the sinus tachycardia of exercise may enhance flecainide-induced conduction slowing by increasing use-dependent sodium channel blockade, thereby facilitating the occurrence of ventricular reentry. To evaluate the modulation of flecainide's effects by exercise, we studied 19 patients who were receiving therapeutic doses of flecainide for the treatment of cardiac arrhythmias. Sixteen patients underwent treadmill exercise testing by a modified Bruce protocol.
During exercise, QRS duration increased progressively from 94± 22 msec (mean± SD) at rest to 116±25 msec (p<0.001) at a mean heart rate increase of 84±32 beats/mmn. The patient with the greatest QRS increase developed a monomorphic ventricular tachycardia at peak exercise. At rest, the QRS duration after treatment with flecainide increased 12.1±10.0%o compared with the pretreatment value, and with exercise, the QRS duration increased by a further 28 .1±17.0% compared with the predrug value. We found that the best predictor of further exercise-induced QRS slowing was the change in QRS duration produced by flecainide at rest (r=0.76,p=0.001).
In an age-and disease-matched control group, the QRS duration did not change during exercise that caused a similar heart rate increase. Abrupt increases in heart rate by ventricular pacing during electrophysiologic study in seven patients prolonged their QRS duration as an exponential function of beat number, with an onset rate constant (0.033±0.006/beat) that is comparable to flecainide's rate constant for use-dependent changes in Vmax in vitro. The QRS increases were similar when compared for corresponding heart rate changes produced by ventricular pacing (13.9±3.1%) and by exercise (12 Flecainide-induced reductions in Vmax are substantially augmented by increases in stimulation frequency throughout the physiologic range of heart rates. 17, 18 We reasoned that the sinus tachycardia of exercise may amplify the sodium channel blockade produced by flecainide acetate through rate-dependent mechanisms. This amplification would result in an increase in drug-induced conduction slowing and possibly lead to ventricular arrhythmogenesis in predisposed patients. The purpose of this study was to determine whether flecainide-induced ventricular conduction slowing is increased by exercise and to determine the mechanism responsible for this phenomenon.
Methods

Patient Population
The study group consisted of 19 patients receiving flecainide acetate for the treatment of cardiac arrhythmias. Six patients not treated with flecainide served as the control group. The characteristics of both groups are summarized in Table 1 during exercise). 21 The significance of regression was determined by an analysis of covariance. Twotailed tests were used for all statistical comparisons, andp<0.05 was considered to be significant.
Results Exercise
In all patients receiving flecainide, QRS duration increased progressively during exercise from 94± 22 to 116+25 msec (p<0.001) at a mean heart rate increase of 84±32 beats/min (Figure 1, top) . In the control group, the QRS duration was 79±10 msec before and 80±11 msec (NS) after exercise, which caused a heart rate increase of 84±29 beats/min (Figure 1, bottom) . The patient receiving flecainide who had the greatest QRS increase during exercise developed a ventricular tachycardia at peak heart rate. His ventricular tachycardia (Figure 2 , bottom) was monomorphic and was sustained for 30 seconds, after which it terminated spontaneously. This patient had had a previous exercise test while not receiving flecainide and had shown neither arrhythmia nor QRS prolongation at a similar work load.
The QRS durations of patients before treatment were compared with those of patients at rest and at peak exercise during treatment with flecainide. The QRS duration of patients at rest after treatment with flecainide increased by 12.1± 10.0% compared with the pretreatment value. During exercise, the QRS increased a further 28.1 + 17.0% compared with the predrug value. Stepwise multilinear regression analysis showed that the only variable that significantly correlated with the extent of exerciseinduced QRS increase was the percent increase in QRS duration on the resting ECG produced by flecainide compared with pretreatment values (r=0.76, p=0.001). The only other variable that improved the multilinear correlation coefficient was the percent heart rate increase resulting from exercise, which improved the r value to 0.84 (p<0.001) when included in the analysis. Neither flecainide dose nor serum flecainide concentration were independent predictors of the degree of exerciseinduced QRS prolongation.
Electrophysiologic Study
Seven patients who received flecainide were studied during electrophysiologic testing. In all seven, abrupt changes in heart rate by ventricular pacing increased QRS duration. Changes in QRS duration after the onset of ventricular pacing followed an exponential relation with beat number (Figure 3 ). The mean rate constant for QRS prolongation in the seven patients studied was 0.033+0.006/beat. Four patients underwent both electrophysiologic study and exercise testing. In these four patients, the QRS increase resulting from exercise (12.6±6.7%) was very similar to the QRS QRS=65msec, HR=69/min (Figure 4) .
Discussion
We have shown that flecainide-induced QRS prolongation is increased by exercise. The degree of additional change in QRS duration produced by exercise was similar to that produced by ventricular pacing throughout a corresponding range of heart rates. A comparable degree of exercise did not alter QRS duration in a set of disease-matched control patients. These observations suggest that the tachycardia associated with exercise is the major factor responsible for the additional conduction slowing resulting from exercise in patients treated with flecainide. Although other factors such as autonomic changes and myocardial ischemia may have had a modulating role, the occurrence of exerciseinduced QRS prolongation in patients treated with flecainide while on 8- FIGURE 4 . Bar graphs of rate-dependent changes in QRS duration resultingfrom exercise (hatched bars) and ventricular pacing (solid bars). When a similar degree of heart rate augmentation was produced by either technique (left graph), the corresponding QRS prolongation was very similar (right graph). Results are mean±SD from four patients undergoing both the exercise and pacing protocols. 0.029±+0.006/beat.17 Therefore, our results provide strong evidence that exercise enhances flecainide's effects on ventricular conduction by increasing the drug's rate-dependent interaction with cardiac sodium channels.
Our results provide further insights into the underlying mechanisms of the interaction between exercise and flecainide. In a recent study, Cascio et a122 showed that exercise accentuated the QRS prolongation produced by amiodarone, which also has use-dependent class I properties.23,24 Our study differs from theirs in that we have both evaluated the specific role of heart rate by comparing QRS changes during exercise with those resulting from tachycardia produced by ventricular pacing and studied the onset time course of conduction changes during pacing at a constant frequency. We found that, in patients receiving flecainide, the increase in QRS duration at rest was the most important determinant of the degree of further QRS prolongation resulting from exercise. Similarly, Cascio et a122 found that the degree of amiodarone-induced QRS prolongation at rest is an important predictor of further QRS prolongation produced by exercise. These results are not surprising because the degree of QRS prolongation on the resting ECG is a direct indicator of the drug's pharmacodynamic action of interest.
Antiarrhythmic drugs could have arrhythmogenic actions by a variety of mechanisms, including abnormal impulse formation (afterdepolarizations and abnormal automaticity) and abnormal impulse propagation resulting in reentry.25,26 Class IC drugs do not result in cellular calcium overload or action potential prolongation.12 Therefore, they would be unlikely to produce delayed or early afterdepolarizations.27-29 The most characteristic property of class IC agents is their potent sodium channel In( fIf 1 blocking and conduction-slowing action,'2 which is most readily related to their arrhythmogenic potential in the context of a reentrant arrhythmia mechanism. The ability to sustain reentry depends on a critical balance between conduction velocity and refractoriness in the reentrant circuit.26,30 A potential reentrant circuit could exist, particularly in the presence of heart disease, but if refractoriness exceeded circuit time, no manifest reentry would occur. If a drug slowed conduction in this circuit to the point at which conduction time exceeded refractory period, sustained reentry would then become possible.
The occurrence of this type of arrhythmogenic mechanism should depend on the presence of a preexisting substrate that can support reentry and on the magnitude of drug-induced conduction slowing. Consistent with this mechanism is the observation that flecainide is much more likely to produce proarrhythmic effects in patients with a history of structural heart disease or ventricular tachyarrhythmias or both than in patients without such a history.3' Similarly, flecainide, even at toxic doses, does not induce ventricular arrhythmias in normal dogs,32 but it does cause dose-related arrhythmogenicity in dogs with prior myocardial infarctions. 33 In patients predisposed to develop reentrant ventricular arrhythmias, the enhancement of flecainide-induced conduction slowing by exercise may be sufficient to allow manifest reentry to occur. This may account for the occurrence of ventricular tachycardia in our patient with the greatest exercise-induced conduction slowing and for the occurrence of proarrhythmia described by Anastasiou-Nana et al. 16 Routine exercise testing has been advocated as a means to detect potential proarrhythmic responses to flecainide. 16 Our results indicate that the degree of flecainide-induced QRS prolongation on the resting ECG is a good predictor of further conduction slowing during exercise, and they suggest that changes in the resting ECG could be used to select patients at increased risk of proarrhythmia during exercise. The value of exercise testing for the prediction of proarrhythmia due to flecainide, either routinely or in selected subgroups, needs to be tested prospectively.
We used QRS duration as an indicator of flecainide's effects on ventricular conduction. Recent work with epicardial mapping shows that QRS duration changes accurately reflect antiarrhythmic drug effects on ventricular conduction, provided that the QRS configuration remains constant. 34 The similarity between the onset kinetics that we observed for flecainide's effects on conduction in humans and the values reported for changes in Vmag in vitro'7 indicates the relevance of basic models of antiarrhythmic drug action'-4 to achieve an understanding of the clinical properties of these compounds. Moreover, we have shown that the use-dependent actions described by these models account for exerciseinduced ventricular conduction slowing in patients treated with flecainide. The latter phenomenon may have an important role in producing ventricular proarrhythmic actions in predisposed patients, indicating the potential clinical importance of the ratedependent actions of antiarrhythmic drugs.
